Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

Pediatric Infectious Disease Journal

Volumn 17, Issue 2, 1998, Pages 110-115

  Subramanian, K N Siva ^a   Weisman, Leonard E ^b   Rhodes, Torunn ^c   Ariagno, Ronald ^d   Sánchez, Pablo J ^e   Steichen, Jean ^f   Givner, Laurence B ^g   Jennings, Terese L ^h   Top Jr , Franklin H ⁱ   Carlin, David ⁱ   Connor, Edward ⁱ  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MEDIMMUNE   (United States)

Author keywords

MEDI 493; Monoclonal antibody; Palivizumab; Respiratory syncytial virus

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; PALIVIZUMAB; PLACEBO; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; BRONCHOPULMONARY DYSPLASIA; DOUBLE-BLIND METHOD; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 6844242330     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199802000-00006     Document Type: Article

References (12)

1. Hall CB, Hall BL. Bronchiolitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:612-19.
2. Cunningham CK, McMillan JA Jr, Gross SJ. Rehospitalization for respiratory illness in infants less than 32 weeks gestation. Pediatrics 1991;88:527-32.
3. Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial virus infection. J Pediatr 1988;113:266-71.
4. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
5. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982;301:397-400.
6. PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
7. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
8. Committee on Infectious Diseases, Committee on Fetus and Newborn. American Academy of Pediatrics. Respiratory syncytial virus immune globulin, intravenous: indications for use. Pediatrics 1997;99:645-50.
9. Beeler JA, Coelingh K. Neutralization epitopes of the F protein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989;63:2941-50.
10. Johnson S, Hemming V, Koenig S, et al. Pre-clinical evaluation of MEDI-493, a humanized monoclonal antibody against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
11. Investigational New Drug files. MedImmune, Inc., Gaithersburg, MD.
12. Burbach GJ, Bienzle U, Neuhaus R, et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997;63:478-80.